Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights - Report - MDSpire

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

  • By

  • Esther Ganelin-Cohen

  • Yair Wexler

  • Sraya Kraus

  • Ayal Rozenberg

  • May 1, 2026

  • 0 min

Share

Clinical Outcomes and Safety of Cladribine in Children with POMS

Overview

{'add': 'Specify the comparison metrics used for efficacy.', 'modify': 'Clarify the cohort size.'}

Background

{'add': 'Include specific challenges faced by POMS patients and implications of off-label use.'}

Data Highlights

{'modify': "Ensure table format is consistent and clarify 'similar' for NEDA rates."}

Key Findings

{'add': 'Expand on longitudinal trends of relapse rates with specific data points.'}

Clinical Implications

{'add': 'Discuss potential risks or considerations for cladribine use in pediatric patients.'}

Conclusion

{'add': 'Reiterate the need for further studies to confirm findings and address limitations.'}

References

  1. Drug Safety, 2020 -- Pregnancy Outcomes in the Clinical Trials of Cladribine for Multiple Sclerosis: A Comprehensive Safety Analysis
  2. Blood Cancer Journal, 2022 -- Three Decades of Cladribine Therapy in Hairy Cell Leukemia: Insights from a Multicenter Italian Study on Long-Term Outcomes
  3. Journal of Gastroenterology, 2025 -- Outcomes in Clinical Practice of Ustekinumab, Vedolizumab, and TNF Inhibitors for Very-Early-Onset Inflammatory Bowel Disease: A Multi-Center Cohort Analysis
  4. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis, 2024
  5. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis - PubMed
  6. Bone Marrow Transplantation — Outcomes in Clinical Practice of Brentuximab Vedotin as Follow-up Treatment Post-Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Comprehensive Review and Meta-Analysis
  7. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
  8. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis - PubMed
  9. Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis - PMC

Original Source(s)

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

  • by Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Ayal Rozenberg

  • May 1, 2026

Related Content

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

  • by

  • April 15, 2026

  • 22 min
The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.